Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax…

Continue Reading

News Source: medicalxpress.com